Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies

CAR-T cell therapy: current limitations and potential strategies

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Current Clinical Application of the CAR-T Cell Therapy

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

[Chimeric antigen receptors in oncology: clinical applications and new developments]

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies